In situ breast cancer.

R. S. Henry-Tillman, Vicki Klimberg

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The clinical expression of in situ cancer varies widely but is usually occult. Diagnosis can be made by a variety of minimally invasive techniques. Treatment of lobular carcinoma in situ (LCIS) is patient-directed but generally requires only close follow-up. Mastectomy is the gold standard for ductal carcinoma in situ (DCIS) and is associated with low recurrence rates. Breast conservation therapy (BCT) has become an acceptable alternative. This choice of definitive therapy for DCIS depends largely on the ability to obtain negative margins. Any attempt at BCT should be coupled with the caveat of close postoperative long-term follow-up. Patients diagnosed with LCIS or who have a history of DCIS should be given the options for the use of tamoxifen for the reduction of subsequent development of invasive breast cancer. Risk versus benefits should be clearly defined.

Original languageEnglish (US)
Pages (from-to)199-209
Number of pages11
JournalCurrent Treatment Options in Oncology
Volume1
Issue number3
StatePublished - Aug 2000
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Segmental Mastectomy
Breast Neoplasms
Mastectomy
Tamoxifen
Recurrence
Therapeutics
Neoplasms
Breast Carcinoma In Situ

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

In situ breast cancer. / Henry-Tillman, R. S.; Klimberg, Vicki.

In: Current Treatment Options in Oncology, Vol. 1, No. 3, 08.2000, p. 199-209.

Research output: Contribution to journalReview article

Henry-Tillman, RS & Klimberg, V 2000, 'In situ breast cancer.', Current Treatment Options in Oncology, vol. 1, no. 3, pp. 199-209.
Henry-Tillman, R. S. ; Klimberg, Vicki. / In situ breast cancer. In: Current Treatment Options in Oncology. 2000 ; Vol. 1, No. 3. pp. 199-209.
@article{293b4b92f23d4bde8724b445b67049e6,
title = "In situ breast cancer.",
abstract = "The clinical expression of in situ cancer varies widely but is usually occult. Diagnosis can be made by a variety of minimally invasive techniques. Treatment of lobular carcinoma in situ (LCIS) is patient-directed but generally requires only close follow-up. Mastectomy is the gold standard for ductal carcinoma in situ (DCIS) and is associated with low recurrence rates. Breast conservation therapy (BCT) has become an acceptable alternative. This choice of definitive therapy for DCIS depends largely on the ability to obtain negative margins. Any attempt at BCT should be coupled with the caveat of close postoperative long-term follow-up. Patients diagnosed with LCIS or who have a history of DCIS should be given the options for the use of tamoxifen for the reduction of subsequent development of invasive breast cancer. Risk versus benefits should be clearly defined.",
author = "Henry-Tillman, {R. S.} and Vicki Klimberg",
year = "2000",
month = "8",
language = "English (US)",
volume = "1",
pages = "199--209",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - In situ breast cancer.

AU - Henry-Tillman, R. S.

AU - Klimberg, Vicki

PY - 2000/8

Y1 - 2000/8

N2 - The clinical expression of in situ cancer varies widely but is usually occult. Diagnosis can be made by a variety of minimally invasive techniques. Treatment of lobular carcinoma in situ (LCIS) is patient-directed but generally requires only close follow-up. Mastectomy is the gold standard for ductal carcinoma in situ (DCIS) and is associated with low recurrence rates. Breast conservation therapy (BCT) has become an acceptable alternative. This choice of definitive therapy for DCIS depends largely on the ability to obtain negative margins. Any attempt at BCT should be coupled with the caveat of close postoperative long-term follow-up. Patients diagnosed with LCIS or who have a history of DCIS should be given the options for the use of tamoxifen for the reduction of subsequent development of invasive breast cancer. Risk versus benefits should be clearly defined.

AB - The clinical expression of in situ cancer varies widely but is usually occult. Diagnosis can be made by a variety of minimally invasive techniques. Treatment of lobular carcinoma in situ (LCIS) is patient-directed but generally requires only close follow-up. Mastectomy is the gold standard for ductal carcinoma in situ (DCIS) and is associated with low recurrence rates. Breast conservation therapy (BCT) has become an acceptable alternative. This choice of definitive therapy for DCIS depends largely on the ability to obtain negative margins. Any attempt at BCT should be coupled with the caveat of close postoperative long-term follow-up. Patients diagnosed with LCIS or who have a history of DCIS should be given the options for the use of tamoxifen for the reduction of subsequent development of invasive breast cancer. Risk versus benefits should be clearly defined.

UR - http://www.scopus.com/inward/record.url?scp=0034256282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034256282&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 199

EP - 209

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 3

ER -